The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
A melanocyte lineage program confers resistance to MAP kinase pathway inhibition
Open accessAbstract
Malignant melanomas harbouring point mutations (Val600Glu) in the serine/threonine-protein kinase BRAF (BRAF(V600E)) depend on RAF-MEK-ERK signalling for tumour cell growth. RAF and MEK inhibitors show remarkable clinical efficacy in BRAF(V600E) melanoma; however, resistance to these agents remains a formidable challenge. Global characterization of resistance mechanisms may inform the development of more effective therapeutic combinations. Here we carried out systematic gain-of-function resistance studies by expressing more than 15,500 genes individually in a BRAF(V600E) melanoma cell line treated with RAF, MEK, ERK or combined RAF-MEK inhibitors. These studies revealed a cyclic-AMP-dependent melanocytic signalling network not previously associated with drug resistance, including G-protein-coupled receptors, adenyl cyclase, protein kinase A and cAMP response element binding protein (CREB). Preliminary analysis of biopsies from BRAF(V600E) melanoma patients revealed that phosphorylated (active) CREB was suppressed by RAF-MEK inhibition but restored in relapsing tumours. Expression of transcription factors activated downstream of MAP kinase and cAMP pathways also conferred resistance, including c-FOS, NR4A1, NR4A2 and MITF. Combined treatment with MAPK-pathway and histone-deacetylase inhibitors suppressed MITF expression and cAMP-mediated resistance. Collectively, these data suggest that oncogenic dysregulation of a melanocyte lineage dependency can cause resistance to RAF-MEK-ERK inhibition, which may be overcome by combining signalling- and chromatin-directed therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Notably, sgRNAs targeting ETS2 were significantly depleted, consistent with a previous finding of its emergence as a resistance hit through a gain-of-function screen for resistance to MAPK pathway inhibitors in BRAF V600E melanoma.49”
From Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer (2026) · cites this paper as [49]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Consistent with this, analysis of primary CRC samples from previously published cohorts49 revealed strong positive correlations between SMAD1 expression, FGFR1 and FGFR3 signaling activity, and Paneth cell signatures (Figures S6A and S6B).”
From Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer (2026) · cites this paper as [49]
Experimental — accuracy not yet measuredIn the citing paper
“In melanoma, core regulators of neural crest lineage, MITF and SOX10, regulate the emergence of distinct cell states associated with drug tolerance establishment after treatment [61,82,83,84].”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [82]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationCombined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Self-citationPierce, K. L., Premont, R. T., & Lefkowitz, R. J. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm908 · Cited by 2,712
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,205
Self-citationGarraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S., Beroukhim, R., Milner, D. A., Granter, S. R., Du, J., et al. (2005) · Nature · doi:10.1038/nature03664 · Cited by 1,548
Self-citationCOT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
Self-citationImproved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-63198 · Cited by 1,330
Self-citationBRAF mutation predicts sensitivity to MEK inhibition
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G. A., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2005) · Nature · doi:10.1038/nature04304 · Cited by 1,326
Self-citationRaf-1 activates MAP kinase-kinase
Kyriakis, J. M., App, H., Zhang, X., Banerjee, P. T., Brautigan, D. L., Rapp, U. R., & Avruch, J. (1992) · Nature · doi:10.1038/358417a0 · Cited by 1,263
Hodgkinson, C. A., Moore, K. J., Nakayama, A., Steingrı́msson, E., Copeland, N. G., Jenkins, N. A., & Arnheiter, H. (1993) · Cell · doi:10.1016/0092-8674(93)90429-t · Cited by 1,092
Frederick, D. T., Piris, A., Cogdill, A. P., Cooper, Z. A., Lezcano, C., Ferrone, C. R., Mitra, D., Boni, A., Newton, L. P., Liu, C., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1630 · Cited by 944
Self-citationThe Primary Structure of MEK, a Protein Kinase that Phosphorylates the ERK Gene Product
Crews, C. M., Alessandrini, A., & Erikson, R. L. (1992) · Science · doi:10.1126/science.1411546 · Cited by 930
MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes
Hemesath, T. J., Price, E. R., Takemoto, C. M., Badalian, T. M., & Fisher, D. E. (1998) · Nature · doi:10.1038/34681 · Cited by 631
A public genome-scale lentiviral expression library of human ORFs
Yang, X., Boehm, J. S., Yang, X., Salehi-Ashtiani, K., Hao, T., Shen, Y., Lubonja, R., Thomas, S. R., Alkan, O., Bhimdi, T., et al. (2011) · Nature Methods · doi:10.1038/nmeth.1638 · Cited by 570
Self-citationWu, M., Hemesath, T. J., Takemoto, C. M., Horstmann, M. A., Wells, A. G., Price, E. R., Fisher, D. Z., & Fisher, D. E. (2000) · Genes & Development · doi:10.1101/gad.14.3.301 · Cited by 548
Ahn, S., Olive, M., Aggarwal, S., Krylov, D. Y., Ginty, D. D., & Vinson, C. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.2.967 · Cited by 505
Girotti, M. R., Pedersen, M., Sánchez‐Laorden, B. L., Virós, A., Turajlic, S., Niculescu‐Duvaz, D., Zambon, A., Sinclair, J., Hayes, A. J., Gore, M. E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0386 · Cited by 394
Genetics of melanoma predisposition
Hayward, N. K. (2003) · Oncogene · doi:10.1038/sj.onc.1206445 · Cited by 320
Dumaz, N., Hayward, R., Martin, J., Ogilvie, L. M., Hedley, D., Curtin, J. A., Bastian, B. C., Springer, C. J., & Marais, R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4227 · Cited by 316
Haq, R., Yokoyama, S., Hawryluk, E. B., Jönsson, G. B., Frederick, D. T., McHenry, K. T., PORTER, D. A., Tran, T.-N., Love, K. T., Langer, R., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205575110 · Cited by 229
Self-citationWalton, K. M., Rehfuss, R. P., Chrivia, J. C., Lochner, J. E., & Goodman, R. H. (1992) · Molecular Endocrinology · doi:10.1210/mend.6.4.1350057 · Cited by 218
Aronov, A. M., Tang, Q., Martínez-Botella, G., Bemis, G. W., Cao, J., Chen, G., Ewing, N. P., Ford, P. J., Germann, U. A., Green, J., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900630q · Cited by 152
An Oncogenic Role for ETV1 in Melanoma
Jané-Valbuena, J., Widlund, H. R., Perner, S., Johnson, L. A., Dibner, A. C., Lin, W. M., Baker, A. C., Nazarian, R. M., Vijayendran, K. G., Sellers, W. R., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3092 · Cited by 115
Self-citationTpl-2 acts in concert with Ras and Raf-1 to activate mitogen-activated protein kinase.
Patriotis, C., Makris, A. M., Chernoff, J., & Tsichlis, P. N. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.21.9755 · Cited by 113
Effect of SMURF2 Targeting on Susceptibility to MEK Inhibitors in Melanoma
Smith, M. P., Ferguson, J., Arozarena, I., Hayward, R., Marais, R., Chapman, A., Hurlstone, A. F. L., & Wellbrock, C. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs471 · Cited by 110
Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage
Yokoyama, S., Feige, E., Poling, L. L., Levy, C., Widlund, H. R., Khaled, M., Kung, A. L., & Fisher, D. E. (2008) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2008.00480.x · Cited by 102
MicroSCALE Screening Reveals Genetic Modifiers of Therapeutic Response in Melanoma
Wood, K. C., Konieczkowski, D. J., Johannessen, C. M., Boehm, J. S., Tamayo, P., Botvinnik, O. B., Mesirov, J. P., Hahn, W. C., Root, D. E., Garraway, L. A., et al. (2012) · Science Signaling · doi:10.1126/scisignal.2002612 · Cited by 36
Self-citationCharacterization of MEK1 phosphorylation by the v-Mos protein.
Pham, C. D., Arlinghaus, R. B., Zheng, C., Guan, K., & Singh, B. (1995) · PubMed · Cited by 26
Cited by
Sorted by citations
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Tirosh, I., Izar, B., Prakadan, S. M., Wadsworth, M. H., Treacy, D., Trombetta, J. J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. (2016) · Science · doi:10.1126/science.aad0501 · Cited by 4,944
Self-citationNext-generation characterization of the Cancer Cell Line Encyclopedia
Ghandi, M., Huang, F. W., Jané-Valbuena, J., Kryukov, G. V., Lo, C. C., McDonald, E. R., Barretina, J., Gelfand, E. T., Bielski, C. M., Li, H., et al. (2019) · Nature · doi:10.1038/s41586-019-1186-3 · Cited by 3,394
Self-citationGenome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
Konermann, S., Brigham, M. D., Trevino, A. E., Joung, J., Abudayyeh, O. O., Barcena, C., Hsu, P. D., Habib, N., Gootenberg, J. S., Nishimasu, H., et al. (2015) · Nature · doi:10.1038/nature14136 · Cited by 2,825
A view on drug resistance in cancer
Vasan, N., Baselga, J., & Hyman, D. M. (2019) · Nature · doi:10.1038/s41586-019-1730-1 · Cited by 2,770
Drug resistance in cancer: An overview
Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N., & Sarkar, S. (2014) · Cancers · doi:10.3390/cancers6031769 · Cited by 2,463
Metadata
- Authors
- Johannessen, C. M., Johnson, L. A., Piccioni, F., Townes, A., Frederick, D. T., Donahue, M. K., Narayan, R., Flaherty, K. T., Wargo, J. A., Root, D. E., & Garraway, L. A.
- Affiliations
- Broad Institute (US)
- Massachusetts General Hospital (US)
- Corresponding author
- Garraway, Levi A.
- ORCID
- Venue
- Nature
- Published
- 2013-11-03
- Volume
- 504
- Issue
- 7478
- Pages
- 138-142
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4098832
- OpenAlex
- W2159220884
- Cited by
- 452
- References
- 28
- Citations by year
- 2026: 8 · 2025: 15 · 2024: 19 · 2023: 22 · 2022: 27 · 2021: 32 · 2020: 49 · 2019: 45 · 2018: 36 · 2017: 57 · 2016: 48 · 2015: 41 · 2014: 47 · 2013: 4
- FWCI
- 20.92
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health (DP2OD002750)
- National Human Genome Research Institute (U54HG006093, U01HG006492)
- National Cancer Institute (P50-CA-93683, R33CA155554, P50CA093683, P01CA163222)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- BRAF V600E mutation, cAMP signaling, CREB, MITF, melanocyte lineage, RAF inhibitors, MEK inhibitors, histone deacetylase inhibitors, G protein-coupled receptors, adenylate cyclase, c-fos, drug resistance mechanisms, therapeutic target
- MeSH terms
- Cyclic AMP, Antineoplastic Agents, Humans, Melanocytes, Melanoma, Transcription Factors, Signal Transduction, Gene Expression Regulation, Neoplastic, Drug Resistance, Neoplasm, Cell Lineage, Mitogen-Activated Protein Kinases, Cell Line, Tumor, Protein Kinase Inhibitors, CREB-Binding Protein, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
